Super‐stable homogeneous embolic agents advance the treatment of hepatocellular carcinoma
Authors:
Open Access
- 15 June 2023
- journal article
- Published by Wiley in iRADIOLOGY
- Vol. 1 (2) , 190-194
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (81925019, U1705281, U22A20333, 82202330)
- Fundamental Research Funds for the Central Universities (2020Y4003, 20720200019)
This publication has 12 references indexed in Scilit:
- Superstable homogeneous lipiodol–ICG formulation: initial feasibility and first-in-human clinical application for ruptured hepatocellular carcinomaRegenerative Biomaterials, 2022
- An exploratory human study of superstable homogeneous lipiodol–indocyanine green formulation for precise surgical navigation in liver cancerBioengineering & Translational Medicine, 2022
- A Superstable Homogeneous Lipiodol-Nanoformulation to Overcome the Dilemma of Interventional Embolization ChemotherapyFrontiers in Bioengineering and Biotechnology, 2022
- Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302Liver Cancer, 2022
- Advanced radionuclides in diagnosis and therapy for hepatocellular carcinomaChinese Chemical Letters, 2022
- A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinomaTheranostics, 2022
- Precision Interventional Brachytherapy: A Promising Strategy Toward Treatment of Malignant TumorsFrontiers in Oncology, 2021
- A superstable homogeneous lipiodol-ICG formulation for locoregional hepatocellular carcinoma treatmentJournal of Controlled Release, 2020
- Local and Regional Therapies for Hepatocellular CarcinomaHepatology, 2020
- Role of Hepatic Artery Infusion Chemotherapy in Treatment of Initially Unresectable Colorectal Liver MetastasesJAMA Surgery, 2019